Pancreatic Enzyme Replacement Therapy
The question
To ask the Secretary of State for Health and Social Care, whether he plans to extend access to Pancreatic Enzyme Replacement Therapy.
Answered by Karin Smyth
Clinicians are responsible for making prescribing decisions for their patients, taking into account best prescribing practice and the local commissioning decisions of their respective integrated care boards. They are also expected to take account of appropriate national guidance on clinical and cost effectiveness.
Pancreatic Enzyme Replacement Therapy (PERT) is used by patients with conditions such as chronic pancreatitis, type 2 diabetes, and cystic fibrosis, in addition to being recommended by the National Institute for Health and Care Excellence (NICE) for people with both operable and inoperable pancreatic cancer. The NICE has acknowledged that this is a priority area for quality improvement, and has included PERT in its quality standard for pancreatic cancer.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →